GPR183-mediated immune cell positioning and function: an integrative perspective across ligand gradients, tissue environments, and disease stages
- 1School of Public Health, Guilin Medical University
- 2Guangxi Key Laboratory of Environmental Exposomics and Entire Lifecycle Health, School of Public Health, Guilin Medical University
Abstract
G protein-coupled receptor 183 (GPR183), also known as EBI2, is a chemoattractant receptor whose principal endogenous ligand is 7α,25-dihydroxycholesterol (7α,25-OHC). Its expression varies dynamically across immune-cell subsets and activation states. By sensing local 7α,25-OHC gradients, GPR183 converts tissue metabolic cues into spatial information, thereby regulating immune-cell migration, tissue distribution, and function. Dynamic receptor expression, ligand synthesis and degradation, responding cell type, and the tissue microenvironment collectively shape the direction of pathway activity, whereas intervention studies in animals and longitudinal observations establish disease stage as a temporal coordinate for interpreting divergent effects. Genetic, pharmacological, and cell-engineering studies provide functional evidence that GPR183 contributes to lymphoid-tissue compartmentalization, host defense, inflammatory responses, tissue repair, and tumor-immune remodeling. Analyses of patient tissues and clinical cohorts extend this mechanistic framework to associations with disease activity, treatment response, and prognosis. Three intervention strategies have emerged: receptor agonism, pharmacological inhibition, and immune-cell engineering. The oral antagonist IPG11406 has entered early clinical evaluation, whereas preclinical assessment of other candidate strategies has focused on ligand stability, tissue selectivity, and long-term immune safety. This review integrates current evidence across four dimensions - immune-cell type, the 7α,25-OHC gradient, tissue microenvironment, and disease stage - and organizes the disease-related actions of GPR183 and potential stratified interventions around pathogenic recruitment, protective recruitment, tissue repair, tumor-immune remodeling, and biomarker applications.
Related
- Thyroid FT3-FT4 axis and sarcopenia risk: an integrative perspective
- Localiser-Based Software-Assisted Patient Positioning in Chest CT: A Propensity Score-Matched Study
- Single-lumen tube cuff tamponade and dynamic positioning for bronchoscopy-associated massive airway hemorrhage: a case series
- Fluoroscopic Catheter-Tip Positioning During Internal Jugular TIVAD Placement in Breast Cancer: A Two-Center Retrospective Cohort Study
- Comparison of two automated PGMI-based software tools for breast positioning quality assessment in DBT screening
BibTeX
@article{lin2026gpr183mediated,
title = {{GPR183-mediated immune cell positioning and function: an integrative perspective across ligand gradients, tissue environments, and disease stages}},
author = {Xinrui Lin and Xinyu Dong and Zhe Jiang and Xuekun Xing},
journal = {Frontiers in Immunology},
year = {2026},
month = oct,
doi = {10.3389/fimmu.2026.1816598},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1816598/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - GPR183-mediated immune cell positioning and function: an integrative perspective across ligand gradients, tissue environments, and disease stages
AU - Xinrui Lin
AU - Xinyu Dong
AU - Zhe Jiang
AU - Xuekun Xing
PY - 2026
DA - 2026/10/06
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1816598
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1816598/full
AB - G protein-coupled receptor 183 (GPR183), also known as EBI2, is a chemoattractant receptor whose principal endogenous ligand is 7α,25-dihydroxycholesterol (7α,25-OHC). Its expression varies dynamically across immune-cell subsets and activation states. By sensing local 7α,25-OHC gradients, GPR183 converts tissue metabolic cues into spatial information, thereby regulating immune-cell migration, tissue distribution, and function. Dynamic receptor expression, ligand synthesis and degradation, responding cell type, and the tissue microenvironment collectively shape the direction of pathway activity, whereas intervention studies in animals and longitudinal observations establish disease stage as a temporal coordinate for interpreting divergent effects. Genetic, pharmacological, and cell-engineering studies provide functional evidence that GPR183 contributes to lymphoid-tissue compartmentalization, host defense, inflammatory responses, tissue repair, and tumor-immune remodeling. Analyses of patient tissues and clinical cohorts extend this mechanistic framework to associations with disease activity, treatment response, and prognosis. Three intervention strategies have emerged: receptor agonism, pharmacological inhibition, and immune-cell engineering. The oral antagonist IPG11406 has entered early clinical evaluation, whereas preclinical assessment of other candidate strategies has focused on ligand stability, tissue selectivity, and long-term immune safety. This review integrates current evidence across four dimensions - immune-cell type, the 7α,25-OHC gradient, tissue microenvironment, and disease stage - and organizes the disease-related actions of GPR183 and potential stratified interventions around pathogenic recruitment, protective recruitment, tissue repair, tumor-immune remodeling, and biomarker applications.
SN - 1664-3224
ER -